专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008145754A3 LIGANDS OF HVEM FOR TREATING HEMATOLOGIC MALIGNANCIES AND AUTOIMMUNE DISEASES 审中-公开
标题翻译：用于治疗血液恶性疾病和自发性疾病的HVEM系统
公开(公告)号：WO2008145754A3
公开(公告)日：2009-07-30
申请号：PCT/EP2008056756
申请日：2008-06-02
申请人： INST NAT SANTE RECH MED , UNIV AIX MARSEILLE II , OLIVE DANIEL , TRUNEH ALEMSEGED , PASERO CHRISTINE
发明人： OLIVE DANIEL , TRUNEH ALEMSEGED , PASERO CHRISTINE
IPC分类号： A61K39/395 , A61P35/02 , A61P37/06 , C07K14/705 , C07K16/28
CPC分类号： C07K16/2878 , A61K38/191 , A61K39/39558 , C07K14/70575 , C07K2317/73 , C07K2317/75 , A61K2300/00
摘要： The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases.
摘要翻译：本发明涉及用于治疗血液恶性肿瘤，特别是慢性淋巴细胞性白血病和用于治疗自身免疫性疾病的HVEM的配体。

2. 发明申请

WO2010089411A3 PD-1 ANTIBODIES AND PD-L1 ANTIBODIES AND USES THEREOF 审中-公开
标题翻译： PD-1抗体和PD-L1抗体及其用途
公开(公告)号：WO2010089411A3
公开(公告)日：2010-12-16
申请号：PCT/EP2010051563
申请日：2010-02-09
申请人： UNIV AIX MARSEILLE II , INST NAT SANTE RECH MED , OLIVE DANIEL
发明人： OLIVE DANIEL
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/2827 , C07K2317/55 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.
摘要翻译：本发明涉及PD-1抗体和PD-L1抗体及其用途。

3. 发明申请

WO2012131004A3 ANTIBODIES DIRECTED AGAINST ICOS AND USES THEREOF 审中-公开
标题翻译：反对ICOS的抗体及其用途
公开(公告)号：WO2012131004A3
公开(公告)日：2012-11-22
申请号：PCT/EP2012055735
申请日：2012-03-29
申请人： INST NAT SANTE RECH MED , INST JEAN PAOLI & IRENE CALMETTES , UNIV AIX MARSEILLE , FAGET JULIEN , CAUX CHRISTOPHE , MENETRIER-CAUX CHRISTINE , NUNES JACQUES , OLIVE DANIEL
发明人： FAGET JULIEN , CAUX CHRISTOPHE , MENETRIER-CAUX CHRISTINE , NUNES JACQUES , OLIVE DANIEL
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2818 , A61K2039/505 , C07K16/28 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/56972 , G01N33/57415
摘要： The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
摘要翻译：本发明提供针对ICOS或其衍生物的抗体，其通过抑制ICOS和ICOS-L之间的固定并消除由浆细胞样树突状细胞诱导的Treg的增殖来中和ICOS与Treg的结合。本发明还提供了针对ICOS的抗体或其衍生物，其诱导IL-10和IFNα 产生，诱导CD4 + T细胞增殖，降低Tconv增殖，增加Treg的免疫抑制功能。

4. 发明公开

KR20200133323A ＢＴＮ２에 대해 특이성을 갖는 항체 및 이의 용도 审中-公开
公开(公告)号：KR20200133323A
公开(公告)日：2020-11-27
申请号：KR20207011551
申请日：2018-09-21
申请人： IMCHECK THERAPEUTICS SAS , CENTRE NAT RECH SCIENT , UNIV DAIX MARSEILLE , INST NAT SANTE RECH MED , INST JEAN PAOLI & IRENE CALMETTES
发明人： OLIVE DANIEL , PASERO CHRISTINE
IPC分类号： C07K16/28 , A61K39/00 , A61P3/10 , A61P19/02 , A61P21/00
摘要： 본발명은 BTN2에대해특이성을갖는항체및 이의용도, 특히암 치료에관한것이다.

5. 发明专利

MY185845A ICOS BINDING PROTEINS 未知
公开(公告)号：MY185845A
公开(公告)日：2021-06-13
申请号：MYPI2017702743
申请日：2016-01-26
申请人： GLAXOSMITHKLINE IP DEV LTD , INST NAT SANTE RECH MED , INST JEAN PAOLI & IRENE CALMETTES , UNIV D?AIX MARSEILLE , CENTRE NAT RECH SCIENT
发明人： LIU YAO-BIN , PARMAR RADHA SHAH , MAYES PATRICK , OLIVE DANIEL
IPC分类号： C07K16/28 , A61P31/00 , A61P35/00 , A61P37/00
摘要： The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.

6. 发明专利

AU2019312831A1 Anti-BTN3a antibodies and their use in treating cancer or infectious disorders 未知
公开(公告)号：AU2019312831A1
公开(公告)日：2021-02-18
申请号：AU2019312831
申请日：2019-07-31
申请人： IMCHECK THERAPEUTICS SAS , INST NAT SANTE RECH MED , UNIV AIX MARSEILLE , INST JEAN PAOLI & IRENE CALMETTES , CENTRE NAT RECH SCIENT
发明人： TRUNEH ALEMSEGED , OLIVE DANIEL , PASERO CHRISTINE , DE GASSART AUDE
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , A61P35/02
摘要： The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.

7. 发明专利

ES2794557T3 Anticuerpos que tienen especificidad hacia nectina-4 y usos de los mismos 未知
公开(公告)号：ES2794557T3
公开(公告)日：2020-11-18
申请号：ES16762800
申请日：2016-09-07
申请人： INST NAT SANTE RECH MED , UNIV AIX MARSEILLE , CENTRE NAT RECH SCIENT , INST JEAN PAOLI & IRENE CALMETTES
发明人： LOPEZ MARC , OLIVE DANIEL
IPC分类号： A61K39/395 , A61K38/00 , A61K38/17 , C07K16/28
摘要： Un anticuerpo que tiene especificidad hacia nectina-4 y que tiene - una cadena pesada que comprende i) una H-CDR1 que tiene al menos un 90% de identidad con la HCDR1 de N41mab, ii) una H-CDR2 que tiene al menos un 90% de identidad con la H-CDR2 de N41mab y iii) una H-CDR3 que tiene al menos un 90% de identidad con la H-CDR3 de N41mab y - una cadena ligera que comprende i) una L-CDR1 que tiene al menos un 90% de identidad con la L-CDR1 de N41mab, ii) una L-CDR2 que tiene al menos un 90% de identidad con la L-CDR2 de N41mab y iii) una L-CDR3 que tiene al menos un 90% de identidad con la L-CDR3 de N41mab en el que - la H-CDR1 de N41mab se define mediante la secuencia abarcada desde el residuo de aminoácido de la posición 31 hasta el residuo de aminoácido de la posición 35 en SEQ ID Nº:1, - la H-CDR2 de N41mab se define mediante la secuencia abarcada desde el residuo de aminoácido de la posición 50 hasta el residuo de aminoácido de la posición 65 en SEQ ID Nº:1, - la H-CDR3 de N41mab se define mediante la secuencia abarcada desde el residuo de aminoácido de la posición 98 hasta el residuo de aminoácido de la posición 105 en SEQ ID Nº:1, - la L-CDR1 de N41mab se define mediante la secuencia abarcada desde el residuo de aminoácido de la posición 24 hasta el residuo de aminoácido de la posición 34 en SEQ ID Nº:2, - la L-CDR2 de N41mab se define mediante la secuencia abarcada desde el residuo de aminoácido de la posición 50 hasta el residuo de aminoácido de la posición 56 en SEQ ID Nº:2, y - la L-CDR3 de N41mab se define mediante la secuencia abarcada desde el residuo de aminoácido de la posición 89 hasta el residuo de aminoácido de la posición 96 en SEQ ID Nº:2.

8. 发明专利

AU2016273829B2 ANTIBODIES DIRECTED AGAINST ICOS AND USES THEREOF 未知
公开(公告)号：AU2016273829B2
公开(公告)日：2018-11-01
申请号：AU2016273829
申请日：2016-12-12
申请人： CENTRE LEON BERARD , INST NAT SANTE RECH MED , INST JEAN PAOLI & IRENE CALMETTES , UNIV CLAUDE BERNARD LYON , UNIV AIX MARSEILLE
发明人： FAGET JULIEN , CAUX CHRISTOPHE , MENETRIER-CAUX CHRISTINE , NUNES JACQUES , OLIVE DANIEL
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
摘要： The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNy production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.

9. 发明专利

PH12017501347A1 AGONISTIC ICOS BINDING PROTEINS 未知
公开(公告)号：PH12017501347A1
公开(公告)日：2017-12-11
申请号：PH12017501347
申请日：2017-07-28
申请人： CENTRE NAT RECH SCIENT , GLAXOSMITHKLINE IP DEV LTD , INST NAT SANTE RECH MED , INST JEAN PAOLI AND IRENE CALMETTES , UNIV AIX MARSEILLE
发明人： LIU YAO-BIN , PARMAR RADHA SHAH , MAYES PATRICK , OLIVE DANIEL
IPC分类号： A61P35/00 , A61P31/00 , A61P37/00 , C07K16/28
摘要： The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further, the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.

10. 发明专利

DK1345969T3 Anti-CD28-antistof 未知
公开(公告)号：DK1345969T3
公开(公告)日：2010-11-29
申请号：DK01995797
申请日：2001-12-26
申请人： INST NAT SANTE RECH MED
发明人： SOULILLOU JEAN-PAUL , LAFLAMME GENEVIEVE , VANHOVE BERNARD , OLIVE DANIEL
IPC分类号： C07K16/28 , C12N15/09 , A61K38/00 , A61K39/395 , A61P29/00 , A61P37/06 , A61P37/08 , C07K16/46 , C07K19/00 , C12N5/10 , C12N5/20 , C12N15/13 , C12N15/63 , C12P21/02

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式